Cardiff Oncology Inc. sell shadow
Start price
22.09.20
/
50%
€9.90
Target price
04.11.21
-
Performance (%)
-49.70%
End price
05.11.21
€4.98
Summary
This prediction ended on 05.11.21 with a price of €4.98. The SELL prediction by shadow for Cardiff Oncology Inc. performed very well with a performance of -49.70%. shadow has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Cardiff Oncology Inc. | -5.847% | -5.847% | 101.990% | -59.741% |
iShares Core DAX® | -1.114% | 5.062% | 24.922% | 25.215% |
iShares Nasdaq 100 | 1.816% | 9.828% | 29.548% | 44.324% |
iShares Nikkei 225® | 2.113% | 8.218% | 22.231% | 12.395% |
iShares S&P 500 | 2.038% | 7.448% | 30.358% | 43.899% |
According to shadow what are the pros and cons of Cardiff Oncology Inc. for the foreseeable future?
Pros
Valuable balance sheet
Capable Management
Good culture
Small cyclical dependencies
Cons
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Low dividend yield expected
negative Cash Flow expected
Little Investments for future growth
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Little innovation
Few uniques
Dependend from some customers or products
Growths slower than the competition
Sustainability is little important
Higher risks for its business
Below average Marketposition
Business model of the past or high risk
Little known brand
Comments by shadow for this prediction
In the thread Trovagene diskutieren
Sell Cardiff Oncology Inc.
In the thread Trading Trovagene
Die von shadow gewählte maximale Laufzeit wurde überschritten